Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin

cetuximab

  • You have access
    Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma
    GEORGIOS PETRAKIS, THEODORA MANTSO, MICHAIL I. KOUKOURAKIS, MIHALIS I. PANAYIOTIDIS and SOTIRIS BOTAITIS
    Anticancer Research May 2022, 42 (5) 2363-2374; DOI: https://doi.org/10.21873/anticanres.15715
  • You have access
    Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
    HIROAKI TANIOKA, KEN SHIMADA, AKIHITO TSUJI, MITSUGU KOCHI, HO MIN KIM, TAKAO TAKAHASHI, TADAMICHI DENDA, AKINORI TAKAGANE, TAKANORI WATANABE, MASAHITO KOTAKA, MASATO NAKAMURA, YU SUNAKAWA, MASAHIRO TAKEUCHI, WATARU ICHIKAWA and MASASHI FUJII
    Anticancer Research May 2022, 42 (5) 2675-2681; DOI: https://doi.org/10.21873/anticanres.15745
  • You have access
    Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma
    TOMOFUMI NARUSE, SOUICHI YANAMOTO, MITSUNOBU OTSURU, NOBUHIRO YAMAKAWA, TADAAKI KIRITA, YUKARI SHINTANI, TATSUSHI MATSUMURA, MASAYA OKURA, MASASHI SASAKI, YOSHIHIDE OTA, SHIN-ICHI YAMADA, HIROSHI KURITA, MASAHIRO UMEDA and JAPAN ORAL ONCOLOGY GROUP (JOOG)
    Anticancer Research November 2021, 41 (11) 5785-5791; DOI: https://doi.org/10.21873/anticanres.15395
  • You have access
    PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma
    TOMOYUKI KII, KANAME SAKUMA and AKIRA TANAKA
    Anticancer Research July 2021, 41 (7) 3363-3370; DOI: https://doi.org/10.21873/anticanres.15124
  • Open Access
    Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer
    MOTOYUKI SUZUKI, YUKINORI TAKENAKA, TOSHIHIRO KISHIKAWA, YOSHIFUMI YAMAMOTO, ATSUSHI HANAMOTO, YOICHIRO TOMIYAMA, TAKAHITO FUKUSUMI, TAKAHIRO MICHIBA, NORIHIKO TAKEMOTO, SUSUMU NAKAHARA and HIDENORI INOHARA
    Anticancer Research April 2021, 41 (4) 2045-2051; DOI: https://doi.org/10.21873/anticanres.14973
  • You have access
    Effects of Type of Antibody to EGFR and Hypomagnesemia on Overall Survival in First-line Treatment of Patients With Unresectable Advanced/Recurrent Colorectal Cancer
    MICHIO KIMURA, EISEKI USAMI and TOMOAKI YOSHIMURA
    Anticancer Research December 2020, 40 (12) 7135-7140; DOI: https://doi.org/10.21873/anticanres.14743
  • You have access
    Comparison Between Biweekly and Weekly Cetuximab in Patients With Metastatic Colorectal Cancer: A Meta-analysis
    AKIHISA MATSUDA, TAKESHI YAMADA, SUPASCHIN JAMJITTRONG, SEIICHI SHINJI, RYO OHTA, HIROMICHI SONODA, TUNYAPORN KAMONVARAPITAK, KUMIKO SEKIGUCHI, MASAO MIYASHITA, HIDEYUKI SUZUKI and HIROSHI YOSHIDA
    Anticancer Research June 2020, 40 (6) 3469-3476; DOI: https://doi.org/10.21873/anticanres.14333
  • You have access
    The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
    ONDREJ FIALA, PAVEL OSTASOV, PETR HOSEK, ONDREJ SOREJS, VACLAV LISKA, TOMAS BUCHLER, ALEXANDR POPRACH, RADEK KUCERA, ONDREJ TOPOLCAN, JAN SUSTR, MONIKA SEDIVCOVA and JINDRICH FINEK
    Anticancer Research October 2019, 39 (10) 5645-5652; DOI: https://doi.org/10.21873/anticanres.13761
  • You have access
    Relationship Between EGFR Expression in Oral Cancer Cell Lines and Cetuximab Antibody-dependent Cell-mediated Cytotoxicity
    HIROSHI NAKAMURA, SHIGEHIRO TAMAKI, TAKAHIRO YAGYUU, NOBUHIRO YAMAKAWA, KATSUHIKO HATAKE and TADAAKI KIRITA
    Anticancer Research March 2019, 39 (3) 1275-1282; DOI: https://doi.org/10.21873/anticanres.13238
  • You have access
    Radiolabeling, Characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 Human Lung Cancer Xenografts
    WAN-I KUO, KAI-HUNG CHENG, YA-JEN CHANG, TSUNG-TSE WU, WEI-CHUAN HSU, LIANG-CHENG CHEN and CHIH-HSIEN CHANG
    Anticancer Research January 2019, 39 (1) 183-190; DOI: https://doi.org/10.21873/anticanres.13096

Pages

  • Next
  • 1
  • 2
  • 3
  • 4
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire